Low-molecular-weight heparin (dalteparin) in women with gynecologic malignancy

Obstetrics and Gynecology

Volumn 105, Issue 5, 2005, Pages 1006-1011

  DeBernardo, Robert L ^a   Perkins, Rebecca B ^a   Littell, Ramey D ^a   Krasner, Carolyn N ^a   Duska, Linda R ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DALTEPARIN; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN;

ABDOMINAL BLEEDING; ADULT; AGED; BLEEDING; CANCER CLASSIFICATION; CANCER SURGERY; COMPUTED TOMOGRAPHIC ANGIOGRAPHY; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DOPPLER FLOWMETRY; DRUG EFFICACY; FEMALE; GYNECOLOGIC CANCER; HUMAN; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MEDICAL RECORD; OBESITY; OPERATION DURATION; PRIORITY JOURNAL; PROPHYLAXIS; REVIEW; RISK FACTOR; SIDE EFFECT; TRANSFUSION;

ADULT; AGE DISTRIBUTION; AGED; AGED, 80 AND OVER; COHORT STUDIES; DALTEPARIN; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; GENITAL NEOPLASMS, FEMALE; GYNECOLOGIC SURGICAL PROCEDURES; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; INCIDENCE; INJECTIONS, SUBCUTANEOUS; MIDDLE AGED; PERIOPERATIVE CARE; PROBABILITY; PROSPECTIVE STUDIES; PULMONARY EMBOLISM; RISK ASSESSMENT; SEX DISTRIBUTION; TREATMENT OUTCOME; VENOUS THROMBOSIS;

EID: 17644374495     PISSN: 00297844     EISSN: 1873233X     Source Type: Journal    
DOI: 10.1097/01.AOG.0000153026.61249.c7     Document Type: Article

References (21)

1. Ballard RM, Bradley-Watson PJ, Johnstone FD, Kenney A, McCarthy TG. Low doses of subcutaneous heparin in the prevention of deep vein thrombosis after gynaecological surgery. J Obstet Gynaecol Br Commonw 1973;80:469-72.
2. von Tempelhoff GF, Heilmann L. Antithrombotic therapy in gynecologic surgery and gynecologic oncology. Hematol Oncol Clin North Am 2000;14:1151-69.
3. Clarke-Pearson DL, Coleman RE, Synan IS, Hinshaw W, Creasman WT. Venous thromboembolism prophylaxis in gynecologic oncology: a prospective, controlled trial of low-dose heparin. Am J Obstet Gynecol 1983;145:606-13.
4. Clarke-Pearson DL, Jelovsek FR, Creasman WT. Thromboembolism complicating surgery for cervical and uterine malignancy: incidence, risk factors, and prophylaxis. Obstet Gynecol 1983;61:87-94.
5. Palmer AJ, Koppenhagen K, Kirchhof B, Weber U, Bergemann R. Efficacy and safety of low molecular weight heparin, unfractionated heparin and warfarin for thrombo-embolism prophylaxis in orthopaedic surgery: a meta-analysis of randomized clinical trials. Haemostasis 1997;27:75-84.
6. Kakkar VV. Effectiveness and safety of low molecular weight heparins (LMWH) in the prevention of venous thromboembolism (VTE). Thromb Haemost 1995;74:364-8.
7. Borstad E, Urdal K, Handeland G, Abildgaard U. Comparison of low molecular weight heparin vs. unfractionated heparin in gynecological surgery. II: Reduced dose of low molecular weight heparin. Acta Obstet Gynecol Scand 1992;71:471-5.
8. Crandon AJ, Koutts J. Incidence of post-operative deep vein thrombosis in gynaecological oncology. Aust N Z J Obstet Gynaecol 1983;23:216-9.
9. Schorge JO, Goldhaber SZ, Duska LR, Goodman A, Feldman S. Clinically significant venous thromboembolism after gynecologic surgery. J Reprod Med 1999;44:669-73.
10. Clarke-Pearson DL, Dodge RK, Synan I, McClelland RC, Maxwell GL. Venous thromboembolism prophylaxis: patients at high risk to fail intermittent pneumatic compression. Obstet Gynecol 2003;101:157-63.
11. Clark-Pearson DL, DeLong E, Synan IS, Soper JT, Creasman WT, Coleman RE. A controlled trial of two low-dose heparin regimens for the prevention of postoperative deep vein thrombosis. Obstet Gynecol 1990;75:684-9.
12. Clarke-Pearson DL, Synan IS, Hinshaw WM, Coleman RE, Creasman WT. Prevention of postoperative venous thromboembolism by external pneumatic calf compression in patients with gynecologic malignancy. Obstet Gynecol 1984;63:92-8.
13. Clarke-Pearson DL, Synan IS, Dodge R, Soper JT, Berchuck A, Coleman RE. A randomized trial of low-dose heparin and intermittent pneumatic calf compression for the prevention of deep venous thrombosis after gynecologic oncology surgery. Am J Obstet Gynecol 1993;168:1146-53.
14. Maxwell GL, Synan I, Dodge R, Carroll B, Clarke-Pearson DL. Pneumatic compression versus low molecular weight heparin in gynecologic oncology surgery: a randomized trial. Obstet Gynecol 2001;98:989-95.
15. Samama CM, Gigou F, Ill P. Low-molecular-weight heparin vs. unfractionated heparin in femorodistal reconstructive surgery: a multicenter open randomized study. Enoxart Study Group. Ann Vasc Surg 1995;9:S45-53.
16. Villena-Heinsen C, Schmidt W. Prevention of thrombosis with low molecular weight heparin in gynecology [in German]. Zentralbl Gynakol 1995;117:289-92.
17. Fricker JP, Vergnes Y, Schach R, Heitz A, Eber M, Grunebaum L, et al. Low dose heparin versus low molecular weight heparin (Kabi 2165, Fragmin) in the prophylaxis of thromboembolic complications of abdominal oncological surgery. Eur J Clin Invest 1988;18:561-7.
18. Abu-Hajir M, Mazzeo AJ. The pharmacology of antithrombotic and antiplatelet agents. Anest Clin North Am 1999;17:749-86.
19. Hoppensteadt D, Walenga JM, Fareed J, Bick RL. Heparin, low-molecular-weight heparins, and heparin pentasaccharide: basic and clinical differentiation. Hematol Oncol Clin North Am 2003;17:313-41.
20. Brown JR, Kuter DJ. The effect of unfractionated vs.low molecular weight heparin on tissue factor pathway inhibitor levels in hospital inpatients. Thromb Haemost 2001;85:979-85.
21. Prandoni P. Cancer and thromboembolic disease: how important is the risk of thrombosis? Cancer Treat Rev 2002;28:133-6.